U.S. markets close in 22 minutes
  • S&P 500

    3,603.43
    -37.04 (-1.02%)
     
  • Dow 30

    28,852.78
    -372.83 (-1.28%)
     
  • Nasdaq

    10,635.95
    -101.56 (-0.95%)
     
  • Russell 2000

    1,674.43
    -0.50 (-0.03%)
     
  • Crude Oil

    79.85
    -1.38 (-1.70%)
     
  • Gold

    1,669.20
    +0.60 (+0.04%)
     
  • Silver

    19.00
    +0.29 (+1.54%)
     
  • EUR/USD

    0.9799
    -0.0020 (-0.21%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1153
    +0.0030 (+0.27%)
     
  • USD/JPY

    144.7930
    +0.3500 (+0.24%)
     
  • BTC-USD

    19,703.33
    +278.50 (+1.43%)
     
  • CMC Crypto 200

    450.21
    +6.78 (+1.53%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Phibro Animal Health (NASDAQ:PAHC) investors are sitting on a loss of 37% if they invested three years ago

·3 min read

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. Unfortunately, that's been the case for longer term Phibro Animal Health Corporation (NASDAQ:PAHC) shareholders, since the share price is down 41% in the last three years, falling well short of the market return of around 66%.

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

Check out our latest analysis for Phibro Animal Health

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

Phibro Animal Health saw its EPS decline at a compound rate of 10% per year, over the last three years. The share price decline of 16% is actually steeper than the EPS slippage. So it seems the market was too confident about the business, in the past.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. Dive deeper into the earnings by checking this interactive graph of Phibro Animal Health's earnings, revenue and cash flow.

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Phibro Animal Health's TSR for the last 3 years was -37%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

A Different Perspective

Phibro Animal Health shareholders are down 17% for the year (even including dividends), but the market itself is up 9.0%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 4% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Phibro Animal Health is showing 3 warning signs in our investment analysis , and 2 of those are concerning...

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.